Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IDP 121

Next Previous
Drug Profile

IDP 121

Alternative Names: IDP-121 - IDP Pharma

Latest Information Update: 16 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IDP Pharma
  • Developer IDP Pharma; LEITAT Technological Center; University of Vienna
  • Class Antineoplastics; Peptides
  • Mechanism of Action Proto-oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Haematological malignancies
  • Phase I Multiple myeloma

Most Recent Events

  • 05 Jan 2026 IDP Pharma plans a phase I/II MYCrocytic trial for Small-cell-lung-cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Spain (IV, Infusion) in December 2025 (CTIS2025-521902-17-00)
  • 01 Sep 2023 Phase-I clinical trials in Multiple myeloma in Spain (unspecified route) prior to September 2023 (IDP Pharma pipeline, September 2023)
  • 05 Jun 2023 Phase-I/II clinical trials in Haematological malignancies (In adults, In the elderly) in Spain (IV) (NCT05908409)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top